Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID program to improve prostate cancer diagnosis across South West London. In addition to the six high-resolution Arietta ultrasound systems, the contract also includes six BiopSee image-guided fusion biopsy systems from MedCom (for which Hitachi is a European distributor) to be installed at three major hospitals. Using the two systems together will allow providers to combine multiparametric magnetic resonance imaging (mp-MRI) data with real-time ultrasound, reducing unnecessary biopsies and providing accurate targeting while reducing the number of samples needed.

Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a broad patent for its artificial intelligence (AI) computed tomography (CT) technology. The technology in question forms a vessel suppressed, chest CT series using deep learning and synthetic data modeling. The company said the patent holds promise for improving the detection and diagnosis of lung cancer at an earlier stage while making clinicians more efficient, a first for computer-aided detection (CAD).

A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission tomography/computed tomography (PET/CT) imaging on patient management of biochemically recurrent prostate cancer after initial prostate cancer treatment and negative or equivocal findings on standard-of-care imaging. The LOCATE trial is a prospective, multi-center, open-label study (NCT02680041) conducted at 15 sites in the United States. Its primary endpoint measured the percentage of men with suspected biochemical recurrence of prostate cancer following initial prior therapy whose treatment plan was changed following an 18F fluciclovine PET/CT scan.

Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery of total body irradiation (TBI). TBI is a procedure commonly used to prepare patients being treated for leukemia and multiple myeloma for a bone marrow transplant. It involves irradiation of the entire body, elevating the need for precision, accuracy and homogeneity in radiation dose delivery. The TomoTherapy platform's architecture enables efficient and effective delivery of radiation over large areas of the patient, making it a valuable part of the bone marrow transplantation conditioning regimen.

According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when memory loss is caused by treatable issues other than Alzheimer’s Disease. The study was presented at the 2018 American Academy of Neurology Conference, April 21-27 in Los Angeles.

June 12, 2018 — Viksit Kumar didn’t know his mother had ovarian cancer until it had reached its third stage, too late ...

NewYork-Presbyterian, in collaboration with Weill Cornell Medicine, Columbia University Irving Medical Center and the Fire Department of New York (FDNY), is expanding its fleet of Mobile Stroke Treatment Units (MSTU) to Queens and Brooklyn. Thanks to a generous donation by the W.P. Carey Foundation, this makes NewYork-Presbyterian the first health system in the country to operate three of these advanced units.

June 8, 2018 — Zebra Medical Vision unveiled its Textray chest X-ray research, which will form the basis for a future ...

A new report from the U.S. Food and Drug Administration (FDA) discusses the continued quality, safety and effectiveness of servicing of medical devices by original equipment manufacturers (OEMs) and third-party entities.